Rigel Pharmaceuticals Assumes Development of R343, an Inhaled Syk Inhibitor for Allergic Asthma

Strategic Insights -

Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) has assumed development of R343, an inhaled syk inhibitor for allergic asthma, following Pfizer's decision to exit the allergy and respiratory therapeutic area. Rigel plans to design a Phase 2 clinical trial with R343 later this year. R343 is a promising therapeutic that targets the possible underlying cause of allergic asthma by inhibiting syk in the immune cascade.

Key Takeaways:

  • Rigel Pharmaceuticals has taken over the development of R343, an inhaled syk inhibitor for allergic asthma, from Pfizer.
  • R343 has completed several Phase 1 clinical trials and has shown promising results in terms of safety and efficacy.
  • The drug works by inhibiting syk, a protein tyrosine kinase that plays a pivotal role in IgE receptor signaling in mast cells.
  • R343 has the potential to prevent or stop the immune response to the allergen, which may be effective in the short and long-term control of allergic asthma.
  • Rigel plans to design a Phase 2 clinical trial with R343 later this year to further evaluate its safety and efficacy.
  • Allergies to common allergens such as pollen are a major trigger for allergic asthma, which affects approximately 20 million people in the U.S.
  • Current therapies for allergic asthma include inhaled corticosteroids (ICS) and beta 2 agonists, but these treatments have limitations and may not be effective for everyone.
  • Rigel's R343 represents a new approach to treating allergic asthma, which may offer a more effective and long-term solution for patients.

Statistics:

  • Approximately 20 million people in the U.S. have asthma (Asthma and Allergy Foundation of America).
  • Allergic asthma accounts for 25% of emergency room visits each year, which translates to approximately 2 million visits per year.
  • R343 has exhibited limited full body (systemic) exposure in clinical trials.
  • Rigel plans to design a Phase 2 clinical trial with R343 later this year to further evaluate its safety and efficacy.

Sources:

  • NewsRx.com
  • Clinical Trials Week